Working in a nuclear power plant is not the best way to avoid cancer. Now it turns out that its waste also serves to cure it
If there is a terrifying and mainstream disease, it is cancer: after all, according to the WHOone in five people will develop it at some point in their life. Although in some cases the risk factors vary depending on the type of cancer, working in a nuclear power plant poses some riskas long as there is greater exposure to ionizing radiation, even if there are no accidents or more intense exposure through maintenance work. Paradoxically, the activity of nuclear power plants, which can cause cancer, also serves to generate the basis of the medicine to cure it. And we are not talking about a potentially distant study, but rather something that can already be materialized. In fact, the United Kingdom has already taken a step forward to transform some of its radioactive waste into anti-cancer medication. The world’s first lead-212 radiopharmaceutical ecosystem. Because in the UK they have closed an agreement between the public body Nuclear Decommissioning Authority and the biotechnology company Bicycle Therapeutics for which the latter will have 400 tons of reprocessed uranium to extract the valuable (for the medical industry) lead – 212 for 15 years. Behind Bicycle is Sir Greg Winter, co-founder of the company and winner of the Nobel Prize in Chemistry in 2018. This will provide them with the infrastructure to create the world’s first end-to-end lead-212 radiopharmaceutical ecosystem, from discovery to commercial supply. So explains it Mike Hannay, Chief Product and Supply Chain Officer at Bicycle Therapeutics. The benefits of lead – 212. Lead – 212 is an isotope used in therapeutic contexts thanks to its particular decay properties, so that it emits both alpha and beta particles. While the former provide high-energy, short-range cytotoxicity, the latter have a more extended range, targeting micro-metastasis. In a simplified way, this medically applicable isotope is essential for precision treatments against tumors resistant to other therapies. Thus, it carries radiation and acts directly on cancer cells to destroy tumors, minimizing the damage to the surrounding healthy tissue. This type of technique offers promising results in prostate cancers and neuroendocrine tumors of organs such as the intestine or pancreas. Extracting lead-212 is an arduous task. Converting the waste from nuclear power plants into cancer treatments seems like a fantastic idea for two reasons: because of the cure for cancer itself and the problem of dealing with radioactive waste, one of the great challenges faced by these energy industries, which have also explored other avenues such as take advantage of the remaining energy. But getting here has not been easy: the extraction process of this isotope has been carried out by the United Kingdom National Nuclear Laboratory (UKNNL) with a complex chemical process that requires the isolation of scandalously small quantities of the precursor material from the used nuclear fuel. Thus, first the Thorium-228 is extracted from the reprocessed uranium to later process it into Radium-224. It is then loaded into a lead-212 generator that has been custom-made for Bicycle Therapeutics’ needs by US company SpectronRx. This is a continuous regeneration, producing enough lead-212 to deliver tens of thousands of doses of precision therapy per year. The laboratory explains that the critical part is in the beginning: “The initial precursor material extracted is comparable to finding a single drop of water in an Olympic swimming pool.” From that minute amount, an even smaller fraction of lead-212 is separated. First discover the universe, then cure cancer. In addition to this unexpected use of nuclear power plant waste, in recent weeks a group of researchers from the University of York have evidenced in a study that the intense radiation captured in the beam absorbers of particle accelerators could be reused to produce materials used in cancer therapies. Those particle accelerators They are used, among other things, in experiments to discover the matter of which the universe is composed. In Xataka | The rarest element on Earth aims to cure cancer. And Europe is already accelerating its production In Xataka | We have been believing that bacteria are a weapon against tumors for 150 years. And finally we have discovered how Cover | Jakub Zerdzicki and Ivan S